Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575834 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,180
- Enrollment target
NCT01575834 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 7,180 participants.
The verdict
NCT01575834, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,180 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis
Interventions
- DRUG Placebo
- DRUG Romosozumab
- DRUG Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,180 participants |
| Start Date | 2012-03-15 |
| Est. Completion | 2016-12-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01575834
The ClinicalTrials.gov registry entry for NCT01575834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01575834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01575834 about?
NCT01575834 is a clinical study titled "Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis". The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis
What is the current status of trial NCT01575834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,180 participants. The study started on 2012-03-15. Estimated completion is 2016-12-28.
What interventions are being tested in trial NCT01575834?
The interventions under investigation include: Placebo (DRUG), Romosozumab (DRUG), Denosumab (DRUG).
Who is sponsoring clinical trial NCT01575834?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.